
  
    
      
        Background_NNP
        Chronic_NNP hepatitis_NNP C_NNP virus_NN (_( HCV_NNP )_) infection_NN is_VBZ a_DT slowly_RB
        progressive_JJ disease_NN that_WDT affects_VBZ approximately_RB 2_CD ._. 7_CD million_CD
        persons_NNS in_IN the_DT United_NNP States_NNPS [_NN 1_CD ]_NN ._. Most_JJS persons_NNS with_IN
        hepatitis_NNP C_NNP are_VBP asymptomatic_JJ ,_, although_IN some_DT experience_NN
        fatigue_NN or_CC other_JJ nonspecific_JJ symptoms_NNS [_NN 2_CD 3_CD ]_NN ._. The_DT
        minority_NN progress_NN to_TO cirrhosis_NNS ,_, liver_NN cancer_NN ,_, or_CC liver_NN
        failure_NN [_NN 4_CD 5_CD 6_CD ]_NN ._. Both_DT physicians_NNS and_CC patients_NNS must_MD weigh_VB
        the_DT immediate_JJ harm_NN associated_VBN with_IN treatment_NN for_IN HCV_NNP
        including_VBG side_NN effects_NNS and_CC cost_NN of_IN therapy_NN against_IN
        potential_JJ future_JJ benefits_NNS when_WRB making_VBG treatment_NN decisions_NNS ._.
        Interferon_NNP and_CC ribavirin_NN cause_VBP a_DT number_NN of_IN adverse_JJ effects_NNS
        including_VBG fatigue_NN ,_, flu-like_JJ symptoms_NNS ,_, insomnia_NN ,_, depression_NN ,_,
        cough_NN ,_, and_CC cytopenia_NN [_NN 7_CD 8_CD 9_CD ]_NN ._. The_DT cost_NN of_IN therapy_NN is_VBZ
        approximately_RB $_$ 1_CD ,_, 000_CD per_IN month_NN with_IN additional_JJ charges_NNS for_IN
        laboratory_NN testing_NN and_CC physician_NN 's_POS visits_NNS ._. On_IN the_DT other_JJ
        hand_NN ,_, a_DT sustained_VBN response_NN to_TO therapy_NN is_VBZ associated_VBN with_IN
        persistently_RB undetectable_JJ HCV_NNP RNA_NNP ,_, improved_VBN liver_NN
        histology_NN ,_, and_CC gains_NNS in_IN health-related_JJ quality_NN of_IN life_NN [_NN 10_CD
        11_CD 12_CD ]_NN ._.
        Limited_JJ information_NN is_VBZ available_JJ about_IN physicians_NNS '_POS
        perceptions_NNS of_IN quality_NN of_IN life_NN with_IN hepatitis_NNP C_NNP ._.
        Physicians_NNPS '_POS perspectives_NNS on_IN HCV_NNP and_CC its_PRP$ treatment_NN may_MD
        influence_VB the_DT advice_NN that_IN they_PRP give_VBP to_TO their_PRP$ patients_NNS about_IN
        the_DT disease_NN ._. In_IN the_DT current_JJ study_NN ,_, we_PRP used_VBD utility_NN analysis_NN
        to_TO evaluate_VB physicians_NNS '_POS perspectives_NNS about_IN hepatitis_NNP C_NNP and_CC
        its_PRP$ therapy_NN ._. Utility_NN analysis_NN provides_VBZ a_DT means_NN to_TO quantify_VB
        preference_NN values_NNS about_IN disease_NN states_NNS [_NN 13_CD 14_CD ]_NN ._. The_DT aims_NNS
        of_IN the_DT study_NN were_VBD :_: 1_LS )_) to_TO assess_VB whether_IN physicians_NNS could_MD
        provide_VB utilities_NNS for_IN hepatitis_NNP C_NNP health_NN state_NN constructs_NNS
        using_VBG visual_JJ analog_NN scales_NNS ,_, 2_LS )_) to_TO quantify_VB physicians_NNS '_POS
        judgments_NNS about_IN various_JJ hepatitis_NNP C_NNP health_NN states_NNS ,_, and_CC 3_LS )_)
        to_TO assess_VB physicians_NNS '_POS thresholds_NNS for_IN recommending_VBG
        treatment_NN ._.
      
      
        Methods_NNP
        
          Subjects_NNP and_CC study_NN instrument_NN
          Participants_NNS consisted_VBD of_IN a_DT convenience_NN sample_NN of_IN 113_CD
          physicians_NNS from_IN Illinois_NNP ,_, Iowa_NNP ,_, South_NNP Carolina_NNP ,_, Indiana_NNP ,_,
          and_CC Michigan_NNP ._. Physicians_NNPS were_VBD surveyed_VBN when_WRB they_PRP attended_VBD
          continuing_VBG medical_JJ education_NN lectures_VBZ in_IN Gastroenterology_NNP
          given_VBN in_IN 1999_CD ._. The_DT questionnaire_NN was_VBD administered_VBN using_VBG a_DT
          paper_NN and_CC pencil_NN format_NN and_CC was_VBD completed_VBN before_IN the_DT
          lecture_NN ._. Demographic_NNP information_NN included_VBD gender_NN ,_, race_NN ,_,
          education_NN ,_, and_CC specialty_NN ._. Participants_NNS were_VBD asked_VBN if_IN they_PRP
          treated_VBD patients_NNS with_IN Hepatitis_NNP C_NNP ._. Five_CD hepatitis_NNP C_NNP
          health_NN states_NNS (_( HS_NNP )_) were_VBD described_VBN ranging_VBG from_IN HS_NNP 1_CD -_: No_DT
          Symptoms_NNP ,_, No_DT Cirrhosis_NNP to_TO HS_NNP 5_CD -_: Severe_NNP Symptoms_NNP ,_, Cirrhosis_NNP
          (_( Table_NNP 1_LS )_) ._. The_DT descriptions_NNS of_IN the_DT hepatitis_NNP C_NNP health_NN
          states_NNS were_VBD developed_VBN based_VBN on_IN the_DT findings_NNS of_IN our_PRP$
          previous_JJ study_NN of_IN symptoms_NNS in_IN patients_NNS with_IN HCV_NNP [_NN 3_CD ]_NN and_CC
          on_IN a_DT consensus_NN of_IN a_DT group_NN of_IN hepatologists_NNS experienced_VBN in_IN
          managing_VBG patients_NNS with_IN hepatitis_NNP C_NNP ._. The_DT description_NN of_IN
          the_DT side_NN effects_NNS of_IN treatment_NN was_VBD based_VBN on_IN published_VBN
          accounts_NNS of_IN the_DT adverse_JJ effects_NNS of_IN interferon_NN and_CC
          ribavirin_NN [_NN 7_CD 8_CD 9_CD 15_CD ]_NN ._.
          Physicians_NNPS rated_VBD hepatitis_NNP C_NNP health_NN states_NNS using_VBG a_DT
          visual_JJ analog_NN scale_NN where_WRB 0_CD %_NN represented_VBD death_NN and_CC 100_CD %_NN
          corresponded_VBD to_TO life_NN without_IN hepatitis_NNP C_NNP ._. We_PRP designated_VBN
          life_NN without_IN hepatitis_NNP C_NNP as_IN the_DT highest_JJS preference_NN value_NN
          and_CC assessed_VBN preferences_NNS for_IN the_DT health_NN state_NN hepatitis_NNP C_NNP
          with_IN No_DT Symptoms_NNP ,_, No_DT cirrhosis_NNS because_IN the_DT psychological_JJ
          impact_NN of_IN having_VBG a_DT disease_NN can_MD effect_VB health_NN status_NN in_IN
          the_DT absence_NN of_IN physical_JJ symptoms_NNS ._. Physicians_NNPS also_RB rated_VBN
          side_NN effects_NNS of_IN antiviral_JJ therapy_NN for_IN hepatitis_NNP C_NNP on_IN a_DT
          visual_JJ analog_NN scale_NN ._. Finally_RB ,_, participating_VBG physicians_NNS
          provided_VBD their_PRP$ threshold_NN for_IN recommending_VBG antiviral_JJ
          therapy_NN ._. That_DT is_VBZ ,_, the_DT sustained_VBN virologic_JJ response_NN rate_NN
          that_IN they_PRP would_MD require_VB before_IN they_PRP would_MD recommend_VB
          treatment_NN to_TO their_PRP$ patients_NNS ._.
        
        
          Statistical_NNP analysis_NN
          Preference_NNP values_NNS for_IN hepatitis_NNP C_NNP health_NN states_NNS were_VBD
          compared_VBN using_VBG the_DT Kruskal-_NNP Wallis_NNP test_NN ._. The_DT Mann-_NNP Whitney_NNP
          U_NNP test_NN was_VBD used_VBN to_TO evaluate_VB the_DT relationship_NN between_IN
          categorical_JJ demographic_JJ variables_NNS and_CC physicians_NNS '_POS
          preference_NN values_NNS ._. The_DT relationship_NN between_IN continuous_JJ
          demographic_JJ variables_NNS and_CC preference_NN values_NNS was_VBD assessed_VBN
          by_IN the_DT Spearman_NNP test_NN ._. This_DT test_NN also_RB was_VBD used_VBN to_TO evaluate_VB
          for_IN an_DT association_NN between_IN preference_NN values_NNS for_IN
          hepatitis_NNP C_NNP health_NN states_NNS ,_, ratings_NNS of_IN side_NN effects_NNS of_IN
          antiviral_JJ therapy_NN ,_, and_CC treatment_NN threshold_NN ._.
        
      
      
        Results_NNS
        Demographic_NNP data_NNS for_IN the_DT participating_VBG physicians_NNS are_VBP
        presented_VBN in_IN Table_NNP 2_CD ._. The_DT majority_NN was_VBD primary_JJ care_NN
        physicians_NNS (_( 81_CD %_NN )_) ,_, including_VBG Internists_NNP and_CC Family_NNP
        Practitioners_NNP ._.
        Physicians_NNPS '_POS preference_NN values_NNS for_IN the_DT hepatitis_NNP C_NNP health_NN
        states_NNS are_VBP shown_VBN in_IN Figure_NN 1_CD ._. Utility_NNP values_NNS decreased_VBD as_IN
        health_NN state_NN severity_NN increased_VBD (_( p_NN <_NN 0_CD ._. 001_CD )_) ._. The_DT median_JJ
        preference_NN value_NN for_IN HS_NNP 1_CD -_: No_DT Symptoms_NNP ,_, No_DT Cirrhosis_NNP was_VBD 88_CD %_NN
        (_( interquartile_NN range_NN 75_CD %_NN -_: 95_CD %_NN )_) corresponding_JJ to_TO a_DT 12_CD %_NN
        reduction_NN from_IN life_NN without_IN hepatitis_NNP C_NNP ._. In_IN contrast_NN the_DT
        median_JJ preference_NN value_NN for_IN HS_NNP 5_CD -_: Severe_NNP Symptoms_NNP ,_, Cirrhosis_NNP
        was_VBD only_RB 18_CD %_NN (_( interquartile_NN range_NN 8_CD %_NN -_: 30_CD %_NN )_) ._.
        The_DT median_JJ preference_NN value_NN for_IN life_NN with_IN the_DT side_NN
        effects_NNS of_IN antiviral_JJ therapy_NN was_VBD 47_CD %_NN (_( interquartile_NN range_NN
        23_CD %_NN -_: 55_CD %_NN )_) ._. That_DT is_VBZ ,_, physicians_NNS felt_VBD that_IN side_NN effects_NNS were_VBD
        associated_VBN with_IN a_DT 53_CD %_NN reduction_NN from_IN good_JJ health_NN ._. After_IN
        considering_VBG the_DT HCV_NNP health_NN states_NNS and_CC the_DT side_NN effects_NNS of_IN
        therapy_NN ,_, physicians_NNS indicated_VBD that_IN they_PRP would_MD require_VB a_DT
        median_NN of_IN a_DT 60_CD %_NN sustained_VBD response_NN rate_NN (_( interquartile_NN
        range_NN 40_CD %_NN -_: 80_CD %_NN )_) before_IN recommending_VBG treatment_NN ._. Only_RB 13_CD %_NN of_IN
        participating_VBG physicians_NNS would_MD accept_VB the_DT 30_CD %_NN response_NN rate_NN
        offered_VBN by_IN current_JJ antiviral_JJ therapy_NN for_IN patients_NNS with_IN HCV_NNP
        genotype_NN 1_CD disease_NN (_( Figure_NN 2_LS )_) ._.
        Health_NN state_NN utility_NN values_NNS did_VBD not_RB vary_VB significantly_RB
        with_IN physicians_NNS '_POS age_NN ,_, gender_NN ,_, race_NN ,_, specialty_NN or_CC whether_IN
        they_PRP treated_VBD hepatitis_NNP C_NNP ._. Ratings_NNS of_IN side_NN effects_NNS and_CC
        thresholds_NNS for_IN recommending_VBG treatment_NN were_VBD similar_JJ across_IN
        the_DT demographic_JJ variables_NNS ._. There_EX were_VBD no_DT significant_JJ
        correlations_NNS between_IN preference_NN values_NNS for_IN hepatitis_NNP C_NNP
        health_NN states_NNS ,_, ratings_NNS of_IN side_NN effects_NNS of_IN therapy_NN ,_, and_CC
        treatment_NN thresholds_NNS ._.
      
      
        Discussion_NNP
        In_IN the_DT current_JJ study_NN ,_, we_PRP developed_VBD and_CC evaluated_VBN
        descriptions_NNS of_IN hepatitis_NNP C_NNP health_NN states_NNS and_CC side_NN effects_NNS
        of_IN antiviral_JJ therapy_NN ._. We_PRP found_VBD that_IN physicians_NNS understood_VBD
        these_DT descriptions_NNS and_CC were_VBD able_JJ to_TO provide_VB utility_NN
        assessments_NNS using_VBG a_DT visual_JJ analog_NN scale_NN ._. Preference_NNP values_NNS
        declined_VBD significantly_RB with_IN increasing_VBG health_NN state_NN
        severity_NN supporting_VBG the_DT validity_NN of_IN the_DT health_NN state_NN
        constructs_NNS ._.
        Physicians_NNPS felt_VBD that_DT hepatitis_NNP C_NNP causes_VBZ a_DT dramatic_JJ
        reduction_NN in_IN health_NN status_NN ._. Even_RB the_DT presence_NN of_IN hepatitis_NNP
        C_NNP ,_, without_IN symptoms_NNS or_CC cirrhosis_NNS (_( HS_NNP 1_LS )_) ,_, was_VBD judged_VBN to_TO
        carry_VB a_DT 12_CD %_NN decrement_NN from_IN life_NN without_IN HCV_NNP ._. Our_PRP$ findings_NNS
        parallel_VB those_DT of_IN a_DT study_NN that_WDT used_VBD the_DT time-trade_JJ off_IN
        method_NN to_TO assess_VB physicians_NNS '_POS preference_NN values_NNS for_IN health_NN
        states_NNS associated_VBN with_IN hepatitis_NNP B_NNP and_CC HIV_NNP [_NN 16_CD ]_NN ._.
        Interestingly_RB ,_, the_DT median_JJ preference_NN value_NN for_IN hepatitis_NNP C_NNP
        without_IN symptoms_NNS in_IN our_PRP$ series_NN was_VBD between_IN that_DT provided_VBD
        for_IN HBV_NNP without_IN symptoms_NNS (_( 92_CD %_NN )_) and_CC HIV_NNP without_IN symptoms_NNS
        (_( 83_CD %_NN )_) in_IN the_DT previous_JJ study_NN [_NN 16_CD ]_NN ._.
        The_DT large_JJ range_NN of_IN physicians_NNS '_POS rating_NN of_IN treatment_NN side_NN
        effects_NNS (_( Figure_NN 1_LS )_) is_VBZ striking_JJ and_CC indicates_VBZ that_IN doctors_NNS '_POS
        views_NNS about_IN the_DT impact_NN of_IN side_NN effects_NNS on_IN health_NN status_NN
        vary_VBP substantially_RB ._. However_RB ,_, the_DT side_NN effects_NNS of_IN antiviral_JJ
        therapy_NN were_VBD judged_VBN severely_RB overall_JJ ,_, with_IN a_DT median_JJ
        preference_NN value_NN of_IN 47_CD %_NN ._. That_DT is_VBZ ,_, time_NN on_IN therapy_NN was_VBD felt_VBN
        to_TO be_VB associated_VBN with_IN a_DT 53_CD %_NN reduction_NN from_IN good_JJ health_NN ._. The_DT
        median_JJ preference_NN value_NN for_IN treatment_NN side_NN effects_NNS was_VBD
        similar_JJ to_TO that_DT provided_VBD for_IN HS_NNP 3_CD -_: Moderate_NNP Symptoms_NNP ,_, No_DT
        Cirrhosis_NNP ._.
        On_IN average_JJ ,_, physicians_NNS indicated_VBD that_IN they_PRP would_MD require_VB
        a_DT 60_CD %_NN sustained_VBD response_NN before_IN recommending_VBG therapy_NN to_TO
        their_PRP$ patients_NNS ._. The_DT 60_CD %_NN threshold_NN far_RB exceeds_VBZ the_DT 30_CD %_NN
        sustained_VBD response_NN rate_NN to_TO interferon_NN and_CC ribavirin_NN therapy_NN
        reported_VBD for_IN patients_NNS with_IN hepatitis_NNP C_NNP genotype_NN 1_CD infection_NN
        [_NN 7_CD 8_CD ]_NN ._. In_IN fact_NN ,_, only_RB 13_CD %_NN of_IN physicians_NNS reported_VBD a_DT
        threshold_NN for_IN recommending_VBG therapy_NN of_IN 30_CD %_NN or_CC less_JJR ._. The_DT
        unfavorable_JJ assessment_NN of_IN treatment_NN side_NN effects_NNS reported_VBN
        by_IN physicians_NNS in_IN the_DT current_JJ study_NN provides_VBZ one_CD explanation_NN
        for_IN relatively_RB low_JJ referral_NN rates_NNS for_IN hepatitis_NNP C_NNP among_IN
        primary_JJ care_NN providers_NNS ._. A_DT survey_NN of_IN primary_JJ care_NN physicians_NNS
        showed_VBD that_IN only_RB 62_CD %_NN refer_VBP anti-_NN HCV_NNP positive_JJ patients_NNS with_IN
        abnormal_JJ transaminase_NN levels_NNS to_TO sub-specialists_JJ [_NN 17_CD ]_NN
        ._.
        The_DT lack_NN of_IN a_DT significant_JJ correlation_NN between_IN the_DT
        respondents_NNS '_POS ratings_NNS of_IN treatment_NN side_NN effects_NNS and_CC their_PRP$
        thresholds_NNS for_IN recommending_VBG treatment_NN is_VBZ surprising_JJ ._. We_PRP
        would_MD expect_VB clinicians_NNS to_TO make_VB decisions_NNS that_WDT are_VBP
        consistent_JJ with_IN their_PRP$ views_NNS on_IN the_DT harm_NN and_CC benefit_NN of_IN a_DT
        particular_JJ therapy_NN ._. Our_PRP$ data_NNS show_VBP that_IN a_DT group_NN of_IN
        physicians_NNS ,_, comprised_VBN largely_RB of_IN primary_JJ care_NN providers_NNS ,_,
        would_MD require_VB a_DT high_JJ degree_NN of_IN benefit_NN in_IN terms_NNS of_IN response_NN
        rate_NN to_TO recommend_VB therapy_NN for_IN HCV_NNP ,_, which_WDT was_VBD not_RB
        necessarily_RB related_VBN to_TO their_PRP$ perspectives_NNS on_IN the_DT harm_NN
        associated_VBN with_IN treatment_NN side_NN effects_NNS ._. The_DT absence_NN of_IN such_JJ
        a_DT relationship_NN may_MD reflect_VB limited_JJ knowledge_NN about_IN
        hepatitis_NNP C_NNP and_CC response_NN rates_NNS to_TO therapy_NN or_CC preconceived_JJ
        notions_NNS about_IN the_DT disease_NN and_CC its_PRP$ treatment_NN ._. This_DT finding_NN
        is_VBZ particularly_RB important_JJ because_IN primary_JJ care_NN providers_NNS
        often_RB decide_VBP whether_IN to_TO refer_VB patients_NNS to_TO a_DT sub-specialist_JJ ._.
        They_PRP also_RB educate_VB patients_NNS and_CC shape_VB their_PRP$ views_NNS about_IN new_JJ
        diagnoses_NNS ._. Continuing_VBG education_NN for_IN physicians_NNS about_IN the_DT
        natural_JJ history_NN and_CC treatment_NN of_IN hepatitis_NNP C_NNP is_VBZ of_IN key_JJ
        importance_NN in_IN helping_VBG them_PRP to_TO provide_VB optimal_NN advice_NN to_TO
        their_PRP$ patients_NNS ._.
        Advances_NNS in_IN antiviral_JJ therapy_NN for_IN hepatitis_NNP C_NNP will_MD
        affect_VB how_WRB physicians_NNS and_CC patients_NNS view_VBP the_DT issue_NN of_IN
        treatment_NN ._. Preliminary_JJ data_NNS suggest_VBP that_IN the_DT combination_NN of_IN
        pegylated_JJ interferon_NN and_CC ribavirin_NN will_MD increase_VB sustained_VBD
        response_NN rates_NNS to_TO more_JJR than_IN 50_CD %_NN overall_JJ ,_, and_CC to_TO greater_JJR
        than_IN 40_CD %_NN in_IN patients_NNS with_IN hepatitis_NNP C_NNP genotype_NN 1_CD infection_NN
        [_NN 18_CD ]_NN ._. Hepatologists_NNP need_VBP to_TO understand_VB other_JJ physicians_NNS '_POS
        perspectives_NNS on_IN hepatitis_NNP C_NNP so_IN that_IN they_PRP can_MD adequately_RB
        address_VB their_PRP$ concerns_NNS about_IN treatment_NN issues_NNS ._.
        Further_RB work_NN is_VBZ needed_VBN to_TO help_VB physicians_NNS to_TO understand_VB
        their_PRP$ patients_NNS '_POS views_NNS on_IN hepatitis_NNP C_NNP ._. A_DT recent_JJ study_NN showed_VBD
        that_IN persons_NNS with_IN hepatitis_NNP C_NNP preferred_VBN to_TO expedite_VB periods_NNS
        of_IN poor_JJ health_NN ,_, implying_VBG that_IN they_PRP may_MD be_VB more_RBR likely_JJ to_TO
        proceed_VB with_IN antiviral_JJ therapy_NN and_CC its_PRP$ attendant_NN side_NN
        effects_NNS than_IN to_TO delay_VB treatment_NN [_NN 19_CD ]_NN ._. In_IN contrast_NN ,_, the_DT
        physicians_NNS in_IN the_DT current_JJ survey_NN had_VBD a_DT relatively_RB high_JJ
        threshold_NN for_IN recommending_VBG treatment_NN ,_, which_WDT would_MD lead_VB them_PRP
        to_TO postpone_VB therapy_NN in_IN the_DT majority_NN of_IN cases_NNS ._. Utility_NN
        analysis_NN may_MD have_VB a_DT role_NN in_IN facilitating_VBG joint_JJ
        decision-making_NN between_IN physicians_NNS and_CC patients_NNS regarding_VBG
        hepatitis_NNP C_NNP ._.
        This_DT study_NN does_VBZ have_VB limitations_NNS ._. We_PRP studied_VBD a_DT
        convenience_NN sample_NN of_IN physicians_NNS attending_VBG continuing_VBG
        medical_JJ education_NN lectures_VBZ ._. The_DT findings_NNS could_MD be_VB biased_VBN
        because_IN we_PRP did_VBD not_RB collect_VB data_NNS on_IN response_NN rates_NNS or_CC on_IN the_DT
        demographic_JJ features_NNS of_IN physicians_NNS who_WP did_VBD not_RB complete_VB the_DT
        survey_NN ._. Furthermore_RB ,_, although_IN the_DT study_NN population_NN
        consisted_VBD largely_RB of_IN primary_JJ care_NN providers_NNS ,_, some_DT
        sub-specialists_JJ were_VBD included_VBN ._. However_RB ,_, the_DT respondents_NNS do_VBP
        represent_VB a_DT cross-section_NN of_IN physicians_NNS who_WP may_MD be_VB involved_VBN
        with_IN the_DT diagnosis_NN of_IN hepatitis_NNP C_NNP ._.
      
      
        Conclusions_NNP
        We_PRP have_VBP developed_VBN and_CC evaluated_VBN health_NN state_NN
        descriptions_NNS for_IN hepatitis_NNP C_NNP ._. Physicians_NNPS felt_VBD that_DT
        hepatitis_NNP C_NNP health_NN states_NNS were_VBD associated_VBN with_IN a_DT
        substantial_JJ decrement_NN in_IN health_NN status_NN ._. Physicians_NNPS provided_VBD
        particularly_RB low_JJ preference_NN values_NNS for_IN side_NN effects_NNS of_IN
        antiviral_JJ therapy_NN and_CC high_JJ thresholds_NNS for_IN recommending_VBG
        treatment_NN ._. However_RB ,_, ratings_NNS of_IN side_NN effects_NNS were_VBD not_RB
        significantly_RB correlated_JJ with_IN thresholds_NNS for_IN recommending_VBG
        therapy_NN ,_, suggesting_VBG that_IN additional_JJ factors_NNS effect_NN
        physicians_NNS views_NNS about_IN antiviral_JJ therapy_NN ._. The_DT use_NN of_IN
        utility_NN analysis_NN could_MD provide_VB a_DT basis_NN for_IN shared_VBN
        decision-making_NN between_IN patients_NNS and_CC their_PRP$ physicians_NNS about_IN
        hepatitis_NNP C_NNP ._.
      
      
        List_NN of_IN Abbreviations_NNP
        HS_NNP (_( health_NN state_NN )_) ,_, HCV_NNP (_( hepatitis_NNP C_NNP virus_NN )_) ,_, RNA_NNP
        (_( ribonucleic_JJ acid_NN )_)
      
      
        Declaration_NNP of_IN Competing_VBG Interests_NNP
        None_NN
      
    
  
